Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells
Related Experiment Video
Updated: Aug 11, 2026
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
Published on: January 14, 2014
Sean D McAllister1, Calvin Chan, Ryan J Taft
1California Pacific Medical Center Research Institute, 475 Brannan St., Suite 220, San Francisco, CA 94107, USA. mcallis@sutterhealth.org
Abstract:
Normal tissue toxicity limits the efficacy of current treatment modalities for glioblastoma multiforme (GBM). We evaluated the influence of cannabinoids on cell proliferation, death, and morphology of human GBM cell lines and in primary human glial cultures, the normal cells from which GBM tumors arise. The influence of a plant derived cannabinoid agonist, Delta(9)-tetrahydrocannabinol Delta(9)-THC), and a potent synthetic cannabinoid agonist, WIN 55,212-2, were compared using time lapse microscopy. We discovered that Delta(9)-THC decreases cell proliferation and increases cell death of human GBM cells more rapidly than WIN 55,212-2. Delta(9)-THC was also more potent at inhibiting the proliferation of GBM cells compared to WIN 55,212-2. The effects of Delta(9)-THC and WIN 55,212-2 on the GBM cells were partially the result of cannabinoid receptor activation. The same concentration of Delta(9)-THC that significantly inhibits proliferation and increases death of human GBM cells has no significant impact on human primary glial cultures. Evidence of selective efficacy with WIN 55,212-2 was also observed but the selectivity was less profound, and the synthetic agonist produced a greater disruption of normal cell morphology compared to Delta(9)-THC.
Insights
Delta-9-tetrahydrocannabinol (Delta(9)-THC) shows selective efficacy against glioblastoma multiforme (GBM) cells, reducing proliferation and increasing cell death without harming normal glial cells. This plant-derived cannabinoid offers a promising therapeutic avenue for GBM treatment.
Area of Science:
- Neuro-oncology
- Pharmacology
- Cell Biology
Background:
- Glioblastoma multiforme (GBM) treatment is limited by normal tissue toxicity.
- Cannabinoids are being investigated for their potential anti-cancer properties.
Purpose of the Study:
- To evaluate the effects of cannabinoids on GBM cells and normal glial cells.
- To compare the efficacy of a plant-derived cannabinoid (Delta(9)-THC) with a synthetic cannabinoid (WIN 55,212-2).
Main Methods:
- Time-lapse microscopy was used to observe human GBM cell lines and primary human glial cultures.
- Cell proliferation, death, and morphology were analyzed.
- Cannabinoid receptor activation was assessed.
Main Results:
- Delta(9)-THC demonstrated more rapid and potent inhibition of GBM cell proliferation and induction of cell death compared to WIN 55,212-2.
- Delta(9)-THC exhibited significant selectivity, impacting GBM cells while sparing normal glial cells.
- WIN 55,212-2 showed less profound selectivity and caused greater disruption to normal cell morphology.
Conclusions:
- Delta(9)-THC selectively targets GBM cells, offering a potential therapeutic advantage over synthetic cannabinoids.
- Cannabinoid receptor activation plays a role in the observed effects.
- Delta(9)-THC represents a promising candidate for developing less toxic GBM therapies.
